{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209160","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.228617+00:00","generated_at":"2026-06-11T17:23:54.199415+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CalciMedica Q2 net loss $6.3M, cash $19.1M; Auxora Phase 2b expands to India, AKI IND expected by year-end","bullets":["Net loss $6.3M ($1.11/sh) in Q2 2023; cash $19.1M expected to fund operations for at least 12 months.","CARPO Phase 2b trial of Auxora in acute pancreatitis with SIRS expanded to India; enrollment complete expected Q1 2024, topline data H1 2024.","IND filing for Auxora in acute kidney injury expected by year-end 2023; trials could begin H1 2024 pending additional funding.","Appointed Raven Jaeger as Chief Regulatory Officer and Andrew Cunningham as SVP Clinical Development; stock relisted on Nasdaq in June.","Preclinical data in JCI Insight show Orai1 inhibition prevents progression of recurrent acute pancreatitis and early chronic pancreatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209160","json":"https://secwatch.observer/filing/0001193125-23-209160.json","markdown":"https://secwatch.observer/filing/0001193125-23-209160.md","text":"https://secwatch.observer/filing/0001193125-23-209160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/d477357d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:23:54.199415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d49daf2f555e9ac4ee8cb5b91ff501d6576aae94","claim":"CalciMedica, Inc. reported three months ended June 30, 2023 results: net income $6.3 million, or $1.11 per share (basic and diluted), EPS $1.11 per share (basic and diluted).","evidence_excerpt":"Net loss was $6.3 million, or $1.11 per share (basic and diluted), and $25.6 million, or $7.86 per share (basic and diluted), for the three and six months ended June 30, 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Net income","value":"$6.3 million, or $1.11 per share (basic and diluted)"},{"label":"EPS","value":"$1.11 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5c021481f4b71f339d87fc419e852c36425cc698","claim":"CalciMedica, Inc. shareholders approved Election of Class III Directors at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 1. Election of Class III Directors The Company’s stockholders elected the two persons listed below as Class III directors, each to serve a three-year term through the Company’s 2026 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"},{"claim_id":"63a1ae4258248b4d6809d9a7d0ced96bc3f31d77","claim":"CalciMedica, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}